Drug Profile
XEN D0101
Alternative Names: XEN-D0101Latest Information Update: 25 Mar 2016
Price :
$50
*
At a glance
- Originator Galapagos NV
- Developer Xention
- Class Antiarrhythmics
- Mechanism of Action Kv1.5 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 25 Mar 2016 Discontinued - Phase-I for Atrial fibrillation in Europe (unspecified route)
- 09 Sep 2011 Phase I development is ongoing in Europe
- 09 Oct 2006 Phase-I clinical trials in Atrial fibrillation in Europe (unspecified route)